SINOMAB BIO-B (03681) rose more than 5% in morning trading. At the time of writing, the stock was up 4.48% to HK$2.1, with a turnover of HK$9.53 million. The company announced that on February 24, 2026, its first-in-class therapeutic product SM17 received Investigational New Drug application approval from China's National Medical Products Administration for the treatment of patients with inflammatory bowel disease. This IND approval marks a significant milestone in expanding the treatment scope of SM17 from atopic dermatitis to IBD, covering chronic and debilitating conditions such as Crohn's disease and ulcerative colitis, which have significant unmet medical needs. The company has completed follow-up for the Phase I bridging study of subcutaneous SM17 in healthy volunteers. The resulting data will support advancing directly to Phase II clinical development for the IBD indication. Concurrent with the IND progress, SM17 is completing a bridging study transitioning from intravenous to subcutaneous formulation, expected to be finalized as early as the first quarter of this year. The company anticipates initiating the Phase II clinical trial for atopic dermatitis as early as the second quarter of this year. SINOMAB views the expansion of SM17's indications from AD to IBD as a major opportunity to address unmet needs in an area of substantial clinical and commercial value.